Movano’s (MOVE) “Speculative Buy” Rating Reiterated at Benchmark

Benchmark reissued their speculative buy rating on shares of Movano (NASDAQ:MOVE) in a report published on Wednesday morning, Benzinga reports. Benchmark currently has a $2.00 price objective on the technology company’s stock.

Movano Stock Up 3.3 %

Movano stock opened at $0.31 on Wednesday. The firm has a market capitalization of $30.56 million, a PE ratio of -0.56 and a beta of 0.12. Movano has a 52 week low of $0.24 and a 52 week high of $1.25. The firm’s 50-day simple moving average is $0.35 and its 200 day simple moving average is $0.42.

Movano (NASDAQ:MOVE) last announced its quarterly earnings results on Wednesday, August 14th. The technology company reported ($0.06) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Movano

Several hedge funds have recently bought and sold shares of MOVE. Quantum Private Wealth LLC boosted its stake in shares of Movano by 113.8% during the second quarter. Quantum Private Wealth LLC now owns 89,139 shares of the technology company’s stock valued at $25,000 after acquiring an additional 47,441 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in Movano in the 4th quarter valued at about $101,000. Mirador Capital Partners LP boosted its stake in shares of Movano by 9.6% during the 1st quarter. Mirador Capital Partners LP now owns 413,204 shares of the technology company’s stock worth $170,000 after purchasing an additional 36,230 shares during the last quarter. Finally, Dorsey & Whitney Trust CO LLC grew its holdings in shares of Movano by 50.0% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 5,630,084 shares of the technology company’s stock worth $1,548,000 after buying an additional 1,876,000 shares in the last quarter. Hedge funds and other institutional investors own 16.64% of the company’s stock.

About Movano

Movano Inc engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking.